Tag: Endospan

Endospan Releases Early TRIOMPHE IDE Study Results at Society of Thoracic Surgeons

HERZLIA, Israel–(BUSINESS WIRE)–Endospan is a pioneer in off-the-shelf endovascular repair of aortic arch disease. As a notice of availability to educate potential referring physicians about the TRIOMPHE study, Endospan shared the 30-day results of the first 22 patients enrolled in the TRIOMPHE IDE study in a Late-Breaking presentation at the 60th […]

Endospan Announces Initial Experience with the Custom-Made NEXUS DUO™ Aortic Arch Stent Graft System

HERZLIYA, Israel–(BUSINESS WIRE)–Endospan, a pioneer in endovascular repair of aortic arch disease, announces the initial experience with its custom-made NEXUS DUO™ Aortic Arch Stent Graft System. Prof. Th. Bisdas, from the Athens Medical Centre, presented the multicentric European experience of the first ten patients treated with NEXUS DUO at the […]

Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS™ Aortic Arch Stent Graft System

HERZLIA, Israel–(BUSINESS WIRE)–Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease received approval from FDA of an investigational device exemption, or IDE, to start the TRIOMPHE study on the NEXUS™ Aortic Arch Stent Graft System (hereinafter referred to as NEXUSTM). Earlier this year, FDA granted NEXUSTM designation as a […]

FDA Grants NEXUS™ Aortic Arch Stent Graft System Breakthrough Designation

Endospan is Granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the NEXUS™ Aortic Arch Stent Graft System. HERZLIA, Israel–(BUSINESS WIRE)–Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease was recently granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for […]

CryoLife Enters Into Distribution Agreement with Endospan

Positions the Company for Accelerating Revenue and Non-GAAP Earnings Growth Over the Next Five Years Conference Call and Webcast Tomorrow, September 12, 2019 at 8:00 a.m. ET ATLANTA, Sept. 11, 2019 /PRNewswire/ — CryoLife, Inc. (“CryoLife”;NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has entered […]

Endospan Appoints Kevin J. Mayberry as CEO

HERZLIA, Israel–(BUSINESS WIRE)–Endospan, a pioneer in off-the-shelf endovascular repair of Aortic Arch Disease including aneurysms and dissections, today announced that it has appointed Kevin J. Mayberry as Chief Executive Officer (CEO), effective immediately. He replaces Alon Shalev, who will continue as a director of Endospan. Previously, Mayberry served in various R&D and […]